ADRIAMYCIN CONTINUOUS I.V. INFUSION-HYPERFRACTIONATED RADIATION THERAPY FOR THE TREATMENT OF RECURRENT PEDIATRIC SOLID TUMORS
| Autor: | Daljit Soni, Barton R. Wald, Jorge A. Ortega, Nomie A. Shore |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Hemangiopericytoma
medicine.medical_specialty business.industry medicine.medical_treatment Hyperfractionated radiation therapy medicine.disease Primary tumor Surgery Radiation therapy Pediatrics Perinatology and Child Health Medicine Sarcoma Radiology business Fibrosarcoma Recurrent pediatric Progressive disease |
| Zdroj: | Pediatric Research. 21:303A-303A |
| ISSN: | 1530-0447 0031-3998 |
| Popis: | The prognosis of most pediatric solid tumors is poor upon development of recurrent disease. The study was designed to test the efficacy of Adriamycin (ADR) I.V. continuous infusion (CI) given simultaneously with hyperfractionated (HFT) radiation therapy (XRT) to such patients. The rationale for the study was: 1. ADR enhances XRT lethality of human cancer cells In vitro by inhibiting XRT repair process. 2. Small doses of XRT when given more than once daily may prevent tumor repopulation to a greater extent than higher doses given once daily. The study consists of ADR I.V. CI 12mg/m2/day x5 days and XRT tumor dose 100 rads twice a day at 6 hours intervals x5 days. Courses were repeated at 3-4 weeks intervals. Three children have been treated; 1 Ewing's sarcoma (ES), 1 fibrosarcoma and 1 hemangiopericytoma, all have previously received ADR 480, 60 and 460mg/m2 respectively. The patient with ES has also received 5400 rads to the primary tumor. All 3 patients achieved partial remission after 2 courses of ADR I.V. CI-HFT-XRT and complete surgical excision of primary tumor was performed in the patient with ES after the 3rd course. Two patients developed progressive disease outside the XRT field 3 and 6 months post-therapy. The 3rd patient's tumor is still under control while receiving the 3rd dose of therapy. This preliminary data suggests that the simultaneous administration of ADR I.V. CI-HFT-XRT can be an effective therapy for recurrent pediatric malignancies and should be tested in a larger number of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|